Staff Editor

15
Jun

FDA Revokes Two Drugs CQ and HCQ Promoted by President Trump to Treat COVID-19

The US FDA Has Revoked the Emergency Use Authorizations (EUA) of Chloroquine and Hydroxychloroquine to Treat COVID-19 The US FDA Has Revoked the Emergency Use Authorizations (EUA) for emergency use of chloroquine phosphate (CQ) and hydroxychloroquine sulfate (HCQ) to treat the COVID-19 disease because BARDA concluded, based on clinical trial data results, that the drug’s potential  benefits do not outweigh

Read more

12
Jun

FDA COVID-19 Related Guidances

COVID-19-Related FDA Guidances The following list of FDA guidances provide recommendations to industry regarding biologics, biologics/drugs, biologics/medical devices, drugs, drugs/biologics, biologics/medical devices, medical devices, food & beverages, biologics, drugs and medical devices during a COVID-19 pandemic.  These guidances discuss FDA’s intended approach to enforcement of regulatory (compliance) requirements for medical products and dietary supplements during a pandemic. Biologics (with Drugs

Read more

10
Jun

Pfizer COVID-19 Clinical Trials

Pfizer: Clinical Trials on COVID-19 Pfizer, a multinational biopharmaceucal giant, is testing few drugs on COVID-19. Xeljanz (tofacitinib) In a multicenter, randomized, double-blind, placebo-controlled, parallel study (phase 2), it is currently evaluating the safety and efficacy of tofacitinib in hospitalized adult subjects* (N=240) with COVID-19 pneumonia. *: subjects with lab confirmed SARS-CoV infection as determined by a positive PCR or

Read more

9
Jun

COVID-19 Developing Drugs and Biological Products

COVID-19: Developing Drugs and Biological Products for Treatment or Prevention During the Coronavirus Disease 2019 (COVID-19) pandemic, US Food and Drug Administration (FDA) has issued a guidance to assist sponsors in clinically developing drugs and biological products intended to treat or prevent COVID-19.  This guidance doesn’t address preventative vaccines and plasma (convalescent).  This guidance is in effect during the COVID-19

Read more

6
Jun

Drugs or Vaccines Being Tested in Patients with COVID-19

Drugs or Vaccines  in Phase 2 Clinical Trials in Patients with COVID-19 This is as of June 7, 2020.   For the interest of understanding currently ongoing clinical trials for a list of representative drugs in patients with COVID-19, the following provides a list of drugs which are currently being tested in phase II clinical trials. In other words, this is

Read more

6
Jun

Specialty Infusion Therapy Drugs

Specialty Infusion Therapy and Drugs Specialty infusion therapy drugs are prescribed for the treatment of both chronic and acute illnesses at home or in the outpatient setting.   About 33% of total drug costs are incurred by specialty drugs according to the 2015 Express Scripts’ Drug Trend Report (PDF available here >>). In 2018, specialty drugs comprised of 44.2% to overall

Read more

19
Oct

AHWP WG5 Clinical Evaluation

AHWP WG5 Clinical Evaluation Clinical Evaluation Working Group 5, Clinical Performance & Safety 2015-11-03 Last Updated: 2020-06-04

24
Nov

Ablation Catheter Approved to Treat Arrhythmia

FDA PMA Approval TactiCath Quartz Contact Force Ablation Catheter and TactiSys Quartz Equipment – P130026 FDA Approval Letter for P130026, Dated October 24, 2014 Summary of Safety and Effectiveness Data (SSED) and Labeling What is it? The TactiCath Quartz Contact Force Ablation Catheter (TactiCath) is a flexible catheter used to treat a certain kind of abnormal heart rhythm (arrhythmia) called paroxysmal

Read more

20
Nov

Common Moles Dysplastic Nevi and Risk of Melanoma

Moles, Dysplastic Nevi, and Risk of Melanoma Key Points A common mole (nevus) is a small growth on the skin that is usually pink, tan, or brown and has a distinct edge. People who have more than 50 common moles have a greater chance than others of developing a dangerous type of skin cancer known as melanoma. Most common moles

Read more

19
Nov

Report for Medication Therapy Management Interventions in Outpatient Settings

By Regulatory Doctor LinkedIn Google Plus Twitter Facebook Comparative Effectiveness Review Medication Therapy Management Interventions in Outpatient Settings This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products

Read more